U.S. Markets closed

Innoviva, Inc. (INVA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
10.23+0.10 (+0.99%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close10.13
Open10.16
Bid10.22 x 800
Ask10.23 x 1100
Day's Range10.11 - 10.26
52 Week Range7.58 - 15.62
Volume615,721
Avg. Volume774,443
Market Cap1.037B
Beta (5Y Monthly)0.78
PE Ratio (TTM)5.09
EPS (TTM)2.01
Earnings DateOct 28, 2020 - Nov 02, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateSep 08, 2015
1y Target Est8.00
  • Innoviva, Inc. (INVA): Hedge Funds Are Cautiously Waiting On The Sidelines
    Insider Monkey

    Innoviva, Inc. (INVA): Hedge Funds Are Cautiously Waiting On The Sidelines

    We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, professional investors have to conduct complex analyses, spend many resources and use tools that are not […]

  • Benzinga

    Overview Of Value Stocks In The Healthcare Sector

    The Meaning Behind Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labeled as a value stock.The following stocks are considered to be notable value stocks in the healthcare sector: 1. Innoviva (NASDAQ: INVA) - P/E: 5.08 2. Jaguar Health (NASDAQ: JAGX) - P/E: 0.02 3. OpGen (NASDAQ: OPGN) - P/E: 2.94 4. Brookdale Senior Living (NYSE: BKD) - P/E: 6.09 5. Ocugen (NASDAQ: OCGN) - P/E: 0.05Innoviva saw an increase in earnings per share from 0.59 in Q1 to 0.69 now. Innoviva does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.Most recently, Jaguar Health reported earnings per share at -0.44, whereas in Q1 earnings per share sat at -0.56. Jaguar Health does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.OpGen has reported Q2 earnings per share at -0.49, which has decreased by 13.95% compared to Q1, which was -0.43. OpGen does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.This quarter, Brookdale Senior Living experienced a decrease in earnings per share, which was 0.09 in Q1 and is now -0.65. Brookdale Senior Living does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.Ocugen has reported Q2 earnings per share at -0.19, which has decreased by 171.43% compared to Q1, which was -0.07. Ocugen does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.These 5 value stocks were selected by Benzinga Insights based on quantified analysis. While this methodical judgment process is not meant to make final decisions, our technology can give investors additional perception into the sector.See more from Benzinga * Options Trades For This Crazy Market: Get Benzinga Options to Follow High-Conviction Trade Ideas * Looking Into Twilio's Return On Capital Employed * 5 Value Stocks In The Real Estate Sector(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • 3 Small-Cap Stocks With Big-Cap Potential
    Motley Fool

    3 Small-Cap Stocks With Big-Cap Potential

    There's no single factor that determines whether a company with a small market cap will eventually grow enough to join the ranks of the largest stocks. Each of the three companies I'll discuss today is competing profitably in the healthcare sector, and each is also exhibiting a robust return on invested capital (ROIC) as well as consistently rising revenues over time. Because the company has no need to sell or develop products, its operating expenses are practically nil, and it has no direct competitors.